Bioventus (NASDAQ:BVS) Updates FY 2026 Earnings Guidance

Bioventus (NASDAQ:BVS) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 0.750-0.790 for the period, compared to the consensus earnings per share estimate of 0.750. The company issued revenue guidance of $600.0 million-$610.0 million, compared to the consensus revenue estimate of $604.7 million.

Analysts Set New Price Targets

Several brokerages recently commented on BVS. Barrington Research raised their target price on Bioventus from $13.00 to $14.00 and gave the stock an “outperform” rating in a research report on Friday, March 6th. Cantor Fitzgerald raised Bioventus to a “strong-buy” rating in a research note on Wednesday, March 4th. Craig Hallum boosted their price target on Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, March 6th. Finally, CJS Securities initiated coverage on Bioventus in a report on Friday, March 27th. They issued a “market outperform” rating and a $14.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $14.00.

Bioventus Trading Down 0.0%

Shares of Bioventus stock traded down $0.01 on Friday, hitting $10.65. 144,375 shares of the company’s stock traded hands, compared to its average volume of 376,928. The firm’s 50-day moving average price is $9.32 and its two-hundred day moving average price is $8.22. The stock has a market capitalization of $885.18 million, a PE ratio of 25.95 and a beta of 0.72. Bioventus has a one year low of $5.81 and a one year high of $11.25. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.70 and a quick ratio of 1.19.

Bioventus (NASDAQ:BVS) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.06. Bioventus had a net margin of 4.94% and a return on equity of 30.75%. The business had revenue of $132.09 million during the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, research analysts expect that Bioventus will post 0.76 EPS for the current fiscal year.

Insider Transactions at Bioventus

In other Bioventus news, Director Michelle Mcmurry-Heath sold 12,000 shares of the stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $8.79, for a total transaction of $105,480.00. Following the completion of the transaction, the director owned 44,997 shares in the company, valued at approximately $395,523.63. This represents a 21.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 33.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Nantahala Capital Management LLC grew its stake in Bioventus by 4.1% in the fourth quarter. Nantahala Capital Management LLC now owns 6,047,403 shares of the company’s stock valued at $44,993,000 after purchasing an additional 236,741 shares in the last quarter. Vanguard Group Inc. increased its holdings in Bioventus by 4.4% during the third quarter. Vanguard Group Inc. now owns 2,924,788 shares of the company’s stock worth $19,567,000 after buying an additional 122,749 shares during the last quarter. Geode Capital Management LLC increased its holdings in Bioventus by 1.8% during the fourth quarter. Geode Capital Management LLC now owns 1,120,238 shares of the company’s stock worth $8,337,000 after buying an additional 19,388 shares during the last quarter. State Street Corp increased its holdings in Bioventus by 1.7% during the fourth quarter. State Street Corp now owns 891,024 shares of the company’s stock worth $6,629,000 after buying an additional 14,590 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in Bioventus by 2.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 765,208 shares of the company’s stock worth $5,693,000 after purchasing an additional 21,777 shares during the period. 62.94% of the stock is currently owned by institutional investors.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.